Bioprofiling Response to Mineralocorticoid Receptor Antagonists for the Prevention of Heart Failure

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 528 participants.

Also called NCT02556450

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose other
Phase
Phase 2
Enrolled
  • 528 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02556450
Other papers using this trial's data
  • Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF JACC. Heart failure, 2021-04 DOI, PubMed 33549556
  • Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial Cardiovascular diabetology, 2021-08-09 DOI, PubMed 34372849, PMC8351439 In the PMC Open Access subset under CC BY.
  • The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial Journal of cardiac failure, 2022-05 DOI, PubMed 34933097
  • Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial Heart (British Cardiac Society), 2024-09-16 DOI, PubMed 38729636, PMC11420742 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
France, Germany, Ireland, Italy, Netherlands, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02556450. Randomized; single masking; primary purpose other. Start 2016-01 (registry gives no type); primary completion 2018-09-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Bioprofiling Response to Mineralocorticoid Receptor Antagonists for the Prevention of Heart Failure
Acronym
Homage
Condition
Heart Failure
Intervention (Drug)
Spironolacton
Lead sponsor
ACS Biomarker (class: other)
Collaborator
Institut National de la Santé Et de la Recherche Médicale, France (class: other government)
Collaborator
London School of Hygiene and Tropical Medicine (class: other)

Record details

Record id
cardio:ct-nct02556450
Content hash
371dc8122c0d3c86389a1a96f803f1104f62828ada115b97f4aff9f1f1cf3bb4